Clinical Trial

A Study of LY4268989 (MORF-057) in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-05-01; most recent amendment 2026-03-26.
Status change: Recruiting → Completed 2026-03-26
Status change: Not Yet Recruiting → Recruiting 2025-05-23
Trial Details
NCT Number NCT06964776
Lead Sponsor Eli Lilly and Company
Conditions Healthy
Enrollment 144 participants
Start Date 2025-05-01
Primary Completion 2026-02-17 (estimated)
Study Completion 2026-02-17 (estimated)
Updated on ClinicalTrials.gov 2026-03-27